Genetic Factors May Influence How 10% of the Population Responds to GLP-1 Drugs
A groundbreaking, decade-long international study led by Stanford Medicine reveals that roughly 1 in 10 people carry genetic variants that make popular GLP-1 diabetes drugs less effective. Published in the journal Genome Medicine, the research introduces a surprising medical phenomenon known as GLP-1 resistance. In individuals with this condition, levels of the blood-sugar-regulating hormone GLP-1 are actually higher than normal, yet their bodies are paradoxically less responsive to it.
The core discovery centers on two genetic variants that handicap a crucial enzyme called PAM, or peptidyl-glycine alpha-amidating monooxygenase. This particular enzyme is highly unique because it is the only one in the human body capable of a chemical process called amidation, which increases the potency and lifespan of active peptides like GLP-1. Researchers initially assumed that people with a broken PAM gene would show lower GLP-1 levels in their blood due to the hormone being less stable. However, human trials revealed the exact opposite: participants with the variant had increased levels of circulating GLP-1, but showed no evidence of higher biological activity. Because their bodies required much more of the hormone to achieve a standard blood sugar reduction, they were effectively resistant to it.
This genetic resistance has a measurable impact on real-world clinical treatment. When analyzing data from three diabetes clinical trials totaling 1,119 participants, researchers found that patients carrying the PAM variants struggled to lower their average blood sugar levels, measured as HbA1c, after six months of GLP-1 therapy. While approximately 25% of standard patients without the variant successfully achieved their target blood sugar goals, that success rate dropped significantly for those with the genetic glitch. Specifically, only 18.5% of patients with the p.D563G variant and a mere 11.5% of patients with the p.S539W variant reached their goals. Crucially, senior author Anna Gloyn noted that this resistance is highly specific to the GLP-1 pathway, as these same patients responded completely normally to other common diabetes medications like metformin, sulfonylureas, and DPP-4i.
While GLP-1 receptor agonists are increasingly prescribed at higher doses for weight loss under brand names like Ozempic and Wegovy, it remains unclear whether these genetic variants affect a patient's ability to lose weight. Only two of the trials analyzed in the study provided weight data, which showed no significant difference between carriers and non-carriers, but researchers emphasize that this data pool is far too limited to draw definitive conclusions. Interestingly, data from two separate pharmaceutical trials using longer-acting GLP-1 formulations showed similar drug responses between both groups, hinting that stronger or extended formulas might naturally override the resistance.
Pinpointing the exact biological mechanism behind GLP-1 resistance remains what researchers call the million-dollar question. Through collaborative experiments on mice, scientists ruled out a few major theories; they confirmed that the PAM defect does not alter the GLP-1 receptors' ability to bind the hormone, nor does it disrupt how the hormone signals through the receptor, meaning the blockage happens further downstream. Gloyn compares the current mystery to insulin resistance, a condition scientists still do not fully understand decades after its discovery but have successfully learned to treat. The ultimate hope is that drug developers can create GLP-1 sensitizers or specialized formulations to bypass this glitch, allowing doctors to use a patient's genetic makeup to get them on the right metabolic medications much faster.
Source: Standford Medicine | April 10, 2026